Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease
Completed
Genzyme, a Sanofi Company
Phase 3
2015-10-28
Primary Objective:
Evaluate long term skeletal response to eliglustat in adult patients who successfully
completed one of the Phase 2 or Phase 3 eliglustat studies.
Secondary Objective:
Evaluate the safety of eliglustat (by [serious] adverse event [AE] continuous monitoring),
the quality of life (Short Form-36 Health Survey [SF-36]) and biomarkers of Gaucher disease
type 1 (GD1) (chitotriosidase, plasma glucosylceramide [GL-1] and lyso glucosylceramide
[lyso-GL-1]) in adult patients who successfully completed one of the Phase 2 or Phase 3
studies.
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Recruiting
Sanofi
Phase 3
2018-04-11
Primary Objective:
Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to <18 years
old).
Secondary Objective:
Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to <18
years old).
Evaluation of the safety in the combination usage of Cerdelga and Cerezyme in type III
Gaucher disease patients and the efficacy on soft tissue diseases.
Evaluation of the safety in the combination usage of Cerdelga and Cerezyme in type III
Gaucher disease patients and the efficacy on soft tissue diseases.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
